8-K current report · filed Aug 13, 2026

ARS Pharmaceuticals, Inc. (SPRY) 8-K Current Report: August 13, 2026

Item EX-99.1Item 2.02SPRY overview

Short answer

ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.

ARS Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed earnings release and financial performance information

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $33.7M, including $26.2M neffy product revenue versus $12.8M in Q2 2025
  • U.S. neffy market share reached 5%, while field-targeted accounts reached 8% versus 4% in Q2 2025
  • Q2 net loss $62.3M, or $0.63 per share, with operating expenses of $95.1M
  • Cash, equivalents, and short-term investments totaled $143.8M, against $96.7M term loans and $74.9M financing liability
  • H2 2026 cash-based SG&A and R&D guidance $100M–$110M, supporting targeted cash-flow breakeven by end-2027; CSU data expected Q1 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ARS Pharmaceuticals, Inc. 8-K filings

Get the next SPRY 8-K as it lands

Follow SPRY for push alerts, or ask the research agent what this filing means.